Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Baethge

Showing results (111-120 of 193) with videos related to

Pageof 20
Sort By:
Journal of Clinical Psychopharmacology|January 2, 2013
Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depressionTom Bschor, Manfred Uhr, Christopher Baethge, et al.
Lancet (London, England)|July 13, 2025
Global cost of silencing science: editors and publishers have a duty to resistFrank Frizelle, Kamran Abbasi, Vivienne C Bachelet, et al.
Depression and Anxiety|February 11, 2003
Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depressionTom Bschor, Christopher Baethge, Mazda Adli, et al.
International Journal of Psychiatry in Clinical Practice|June 17, 2014
Use of polypharmacy and self-reported mood in outpatients with bipolar disorderMazda Adli, Peter C Whybrow, Paul Grof, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|September 16, 2003
Prophylaxis latency and outcome in bipolar disordersChristopher Baethge, Leonardo Tondo, Irene M Bratti, et al.
Journal of Psychiatry & Neuroscience : JPN|December 6, 2005
Long-term lithium treatment and thyroid antibodies: a controlled studyChristopher Baethge, Holger Blumentritt, Anne Berghöfer, et al.
The International Journal of Neuropsychopharmacology|December 1, 2005
Secular trends in first hospitalizations for major mood disorders with comorbid substance useGian Paolo Minnai, Leonardo Tondo, Piergiorgio Salis, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 16, 2002
Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disordersMichael Bauer, Anne Berghöfer, Tom Bschor, et al.
Neuropsychobiology|August 18, 2009
Long-term outcome after lithium augmentation in unipolar depression: focus on HPA system activityMazda Adli, Tom Bschor, Michael Bauer, et al.
Journal of Affective Disorders|November 24, 2004
Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal studyMichael Bauer, Lynn Fairbanks, Anne Berghöfer, et al.
Pageof 20

Showing results (111-120 of 193) with videos related to

Sort By:
Pageof 20
Journal of Clinical Psychopharmacology|January 2, 2013
Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depressionTom Bschor, Manfred Uhr, Christopher Baethge, et al.
Lancet (London, England)|July 13, 2025
Global cost of silencing science: editors and publishers have a duty to resistFrank Frizelle, Kamran Abbasi, Vivienne C Bachelet, et al.
Depression and Anxiety|February 11, 2003
Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depressionTom Bschor, Christopher Baethge, Mazda Adli, et al.
International Journal of Psychiatry in Clinical Practice|June 17, 2014
Use of polypharmacy and self-reported mood in outpatients with bipolar disorderMazda Adli, Peter C Whybrow, Paul Grof, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|September 16, 2003
Prophylaxis latency and outcome in bipolar disordersChristopher Baethge, Leonardo Tondo, Irene M Bratti, et al.
Journal of Psychiatry & Neuroscience : JPN|December 6, 2005
Long-term lithium treatment and thyroid antibodies: a controlled studyChristopher Baethge, Holger Blumentritt, Anne Berghöfer, et al.
The International Journal of Neuropsychopharmacology|December 1, 2005
Secular trends in first hospitalizations for major mood disorders with comorbid substance useGian Paolo Minnai, Leonardo Tondo, Piergiorgio Salis, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 16, 2002
Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disordersMichael Bauer, Anne Berghöfer, Tom Bschor, et al.
Neuropsychobiology|August 18, 2009
Long-term outcome after lithium augmentation in unipolar depression: focus on HPA system activityMazda Adli, Tom Bschor, Michael Bauer, et al.
Journal of Affective Disorders|November 24, 2004
Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal studyMichael Bauer, Lynn Fairbanks, Anne Berghöfer, et al.
Pageof 20